Phase classification • Trial termination • Combination therapy • Checkpoint inhibition • Metastases
|
MSI (Microsatellite instability) • HLA-A (Major Histocompatibility Complex, Class I, A) • HLA-B (Major Histocompatibility Complex, Class I, B)
|
MSI-H/dMMR • HLA-A*02 • HLA-A*24
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • adegramotide/nelatimotide (DSP-7888)